CYD Dengue Vaccine + Placebo (Sodium chloride 0.9%)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dengue Fever
Conditions
Dengue Fever, Dengue Hemorrhagic Fever
Trial Timeline
May 2, 2016 → Apr 29, 2020
NCT ID
NCT02628444About CYD Dengue Vaccine + Placebo (Sodium chloride 0.9%)
CYD Dengue Vaccine + Placebo (Sodium chloride 0.9%) is a phase 2 stage product being developed by Sanofi for Dengue Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT02628444. Target conditions include Dengue Fever, Dengue Hemorrhagic Fever.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02628444 | Phase 2 | Completed |
Competing Products
20 competing products in Dengue Fever